Table 3.
Patient Outcomes According to EGFR Mutation, Copy Number, and Immunohistochemical Positivity or Negativity*
| Assay | Total | Response | P† | Stable | Disease Controlled | P‡ | Disease Progression |
|---|---|---|---|---|---|---|---|
| Mutation | >.0001 | .008 | |||||
| Positive | 19 | 12 (63) | 4 (21) | 16 (84) | 3 (16) | ||
| Negative | 20 | 1 (5) | 7 (35) | 8 (40) | 12 (60) | ||
| Copy number | |||||||
| CISH | 1 | 1 | |||||
| Positive | 15 | 5 (33) | 4 (27) | 9 (60) | 6 (40) | ||
| Negative | 21 | 6 (29) | 7 (33) | 13 (62) | 8 (38) | ||
| FISH | .5 | 1 | |||||
| Positive | 19 | 7 (37) | 5 (26) | 12 (63) | 7 (37) | ||
| Negative | 17 | 4 (24) | 6 (35) | 10 (59) | 7 (41) | ||
| Immunohistochemical results | |||||||
| Score | 1 | .4 | |||||
| Positive | 9 | 3 (33) | 4 (44) | 7 (78) | 2 (22) | ||
| Negative | 22 | 7 (32) | 5 (23) | 12 (55) | 10 (45) | ||
| Intensity | 1 | .2 | |||||
| Positive | 13 | 4 (31) | 6 (46) | 10 (77) | 3 (23) | ||
| Negative | 18 | 6 (33) | 3 (17) | 9 (50) | 9 (50) | ||
| Cutoff | 1 | .3 | |||||
| ≥10% | 20 | 7 (35) | 7 (35) | 14 (70) | 6 (30) | ||
| <10% | 11 | 3 (27) | 2 (18) | 5 (45) | 6 (55) |
EGFR, epidermal growth factor receptor; CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization.
*
Data are given as number (percentage).
†
Reflects comparison of responders in positive vs negative assay groups.
‡
Reflects comparison of all patients with disease control in positive vs negative assay groups; Fisher exact test.